Insider Selling: Beta Bionics (NASDAQ:BBNX) CFO Sells $83,378.88 in Stock

Beta Bionics, Inc. (NASDAQ:BBNX) CFO Stephen Feider sold 4,896 shares of the business’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $17.03, for a total transaction of $83,378.88. Following the transaction, the chief financial officer owned 165,931 shares in the company, valued at approximately $2,825,804.93. The trade was a 2.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Stephen Feider also recently made the following trade(s):

• On Friday, June 26th, Stephen Feider sold 5,104 shares of Beta Bionics stock. The shares were sold at an average price of $17.05, for a total transaction of $87,023.20.
• On Tuesday, June 2nd, Stephen Feider sold 6,676 shares of Beta Bionics stock. The shares were sold at an average price of $12.61, for a total value of $84,184.36.

Beta Bionics Stock Up 0.4%

Shares of BBNX opened at $16.76 on Friday. The stock’s 50-day moving average price is $12.45 and its 200 day moving average price is $15.13. The firm has a market capitalization of $746.86 million, a price-to-earnings ratio of -11.10 and a beta of 3.02. Beta Bionics, Inc. has a 12-month low of $8.80 and a 12-month high of $32.71.

Beta Bionics (NASDAQ:BBNX) last announced its quarterly earnings data on Tuesday, April 21st. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.04. The company had revenue of $27.63 million for the quarter. Beta Bionics had a negative return on equity of 23.00% and a negative net margin of 60.27%. Equities research analysts expect that Beta Bionics, Inc. will post -2.22 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Weiss Ratings cut shares of Beta Bionics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, April 21st. Bank of America cut their price target on shares of Beta Bionics from $23.00 to $11.00 and set a “neutral” rating for the company in a research note on Monday, May 18th. Stifel Nicolaus lowered their price objective on Beta Bionics from $22.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, April 22nd. The Goldman Sachs Group dropped their target price on Beta Bionics from $19.00 to $17.00 and set a “buy” rating for the company in a report on Wednesday, May 27th. Finally, Wall Street Zen downgraded Beta Bionics from a “hold” rating to a “sell” rating in a research report on Sunday, March 29th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Beta Bionics currently has a consensus rating of “Moderate Buy” and an average target price of $19.70.

Institutional Investors Weigh In On Beta Bionics

Large investors have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. boosted its stake in Beta Bionics by 0.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 331,623 shares of the company’s stock worth $10,105,000 after purchasing an additional 931 shares in the last quarter. Deutsche Bank AG increased its stake in shares of Beta Bionics by 3.4% in the fourth quarter. Deutsche Bank AG now owns 39,300 shares of the company’s stock valued at $1,197,000 after buying an additional 1,296 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in shares of Beta Bionics by 203.6% in the third quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock valued at $47,000 after buying an additional 1,594 shares in the last quarter. Summit Securities Group LLC bought a new position in shares of Beta Bionics in the fourth quarter valued at about $52,000. Finally, Caitong International Asset Management Co. Ltd raised its holdings in shares of Beta Bionics by 1,075.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock valued at $61,000 after buying an additional 1,818 shares during the last quarter.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.